DRUG METABOLISM REVIEWS

Scope & Guideline

Advancing knowledge in pharmacology and toxicology.

Introduction

Delve into the academic richness of DRUG METABOLISM REVIEWS with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN0360-2532
PublisherTAYLOR & FRANCIS LTD
Support Open AccessNo
CountryUnited States
TypeJournal
Converge1972, from 1974 to 2024
AbbreviationDRUG METAB REV / Drug Metab. Rev.
Frequency4 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND

Aims and Scopes

The journal 'Drug Metabolism Reviews' serves as a vital resource for researchers and professionals in pharmacology, toxicology, and drug development, focusing on the complexities of drug metabolism and disposition. Its aims and scopes encompass a wide range of topics within drug metabolism, with an emphasis on both fundamental and applied aspects.
  1. Drug Metabolism Mechanisms:
    Explores the biochemical processes and enzymatic pathways involved in the metabolism of drugs, including phase I and phase II reactions, and the role of cytochrome P450 enzymes.
  2. Pharmacogenetics and Drug Interactions:
    Investigates the genetic factors influencing drug metabolism and the implications of drug-drug and drug-gene interactions on therapeutic outcomes and adverse effects.
  3. Transport Mechanisms in Drug Disposition:
    Focuses on the role of drug transporters in pharmacokinetics, including absorption, distribution, and elimination processes, and their impact on drug efficacy and safety.
  4. Toxicology and Hepatotoxicity:
    Addresses the potential toxic effects of drugs and their metabolites, particularly focusing on hepatotoxicity and the mechanisms underlying drug-induced liver injury.
  5. Biotransformation Research:
    Covers advances in biotransformation studies, including novel methodologies for assessing drug metabolism and the development of predictive models for drug interactions.
  6. Regulatory and Clinical Implications:
    Discusses regulatory guidelines and clinical considerations related to drug metabolism, including in vitro and in vivo methodologies and their translation to clinical practice.
The journal has exhibited a dynamic evolution in its research themes, reflecting the latest advancements in drug metabolism science. This section outlines the trending and emerging scopes that are gaining traction in recent publications.
  1. Pharmacogenomics and Personalized Medicine:
    There is a notable increase in research exploring pharmacogenomics, emphasizing how genetic variations affect drug metabolism and response, thereby supporting the movement towards personalized medicine.
  2. Drug Transporter Studies:
    Emerging interest in the role of drug transporters in drug disposition and interactions is evident, highlighting their significance in pharmacokinetics and the blood-brain barrier.
  3. Innovative Drug Delivery Systems:
    Research on novel drug delivery systems, including nanocarriers and biopolymers, is trending, focusing on improving bioavailability and targeting specific sites, particularly in cancer therapy.
  4. Impact of Gut Microbiota on Drug Metabolism:
    An increasing number of studies are exploring how gut microbiota influences drug metabolism and pharmacokinetics, signifying a growing recognition of the microbiome's role in drug response.
  5. Advanced In Vitro and In Vivo Models:
    The development of sophisticated in vitro and in vivo models for studying drug metabolism and toxicity is on the rise, as researchers seek better predictive tools for clinical outcomes.

Declining or Waning

While 'Drug Metabolism Reviews' continues to be a leading journal in the field, certain themes have shown a decline in focus or frequency of publication. This section highlights these waning scopes, indicating shifts in research priorities or emerging interests.
  1. Natural Product Drug Interactions:
    Research on the pharmacokinetic interactions involving natural products has decreased, possibly due to a growing emphasis on synthetic drug development and biopharmaceuticals.
  2. General Toxicogenomics:
    While still relevant, the broad application of toxicogenomics in drug metabolism studies has seen a reduction in publications, as researchers increasingly focus on specific mechanisms and pathways.
  3. Traditional Pharmacokinetics:
    The traditional approaches to pharmacokinetics are being overshadowed by novel methodologies and advanced technologies, leading to fewer publications centered on classical pharmacokinetic principles.
  4. Basic Mechanisms of Drug Resistance:
    Studies focused solely on the basic mechanisms of drug resistance, without integration into broader clinical or translational contexts, have become less frequent as the field shifts towards targeted therapies and personalized medicine.

Similar Journals

CLINICAL PHARMACOKINETICS

Illuminating Pathways in Clinical Pharmacology
Publisher: ADIS INT LTDISSN: 0312-5963Frequency: 12 issues/year

CLINICAL PHARMACOKINETICS, published by ADIS INT LTD, is a premier journal dedicated to the field of pharmacology, with a distinguished reputation since its inception in 1976. With an impressive impact factor and categorized in the Q1 quartile for both general pharmacology and medical pharmacology, this journal ranks #29 out of 272 and #53 out of 313 in its respective categories in Scopus, highlighting its high academic influence and the quality of research it publishes. CLINICAL PHARMACOKINETICS serves as a vital resource for researchers, professionals, and students interested in the latest advancements in drug metabolism, therapeutic efficacy, and clinical applications of pharmacokinetic studies. As it continues to evolve through 2024 and beyond, the journal remains committed to fostering a deeper understanding of pharmacotherapy and its implications in clinical practice. While it does not currently offer open access, the journal ensures that cutting-edge research is accessible through various academic platforms.

Translational and Clinical Pharmacology

Empowering Pharmacological Insights for Tomorrow
Publisher: KSCPTISSN: 2289-0882Frequency:

Translational and Clinical Pharmacology, published by KSCPT, is an esteemed journal that serves as a vital source of knowledge in the field of pharmacology, particularly focusing on the translational aspects that bridge laboratory research and clinical applications. Established in 2014, this journal aims to disseminate high-quality research and reviews pertaining to drug development, therapeutics, and the underlying mechanisms of action in the medical realm. With an ISSN of 2289-0882 and an E-ISSN of 2383-5427, it holds a significant position with a Q3 ranking in the pharmacology category as of 2023, emphasizing its role in advancing scientific understanding within this crucial discipline. While it operates as a traditional subscription-based journal, its output remains accessible through various academic platforms, contributing to the global discourse in pharmacology. Researchers, professionals, and students will find value in its insightful articles and comprehensive studies, underscoring the journal’s commitment to enhancing pharmacological knowledge and practice.

CURRENT DRUG METABOLISM

Pioneering Insights for Clinical Biochemistry
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1389-2002Frequency: 14 issues/year

CURRENT DRUG METABOLISM, published by Bentham Science Publishers Ltd, serves as a pivotal resource in the fields of Clinical Biochemistry and Pharmacology. With an ISSN of 1389-2002 and an E-ISSN of 1875-5453, this journal has carved a niche since its inception in 2000, offering in-depth research and reviews that bridge the gap between drug metabolism and its clinical applications. The journal finds itself positioned in the third quartile (Q3) for both Clinical Biochemistry and Pharmacology as of 2023, reflecting its significance within these scientific sectors, with Scopus rankings showcasing its role in advancing knowledge—rank #167 in Pharmacology and #66 in Clinical Biochemistry. Researchers and industry professionals are encouraged to contribute their findings, fostering a diverse platform that informs and inspires innovations in drug development and safety. While CURRENT DRUG METABOLISM operates under a traditional subscription model without open access, its rigorous peer-review process ensures the quality and integrity of the published work, making it indispensable for anyone engaged in drug research and biochemistry.

XENOBIOTICA

Connecting Research with Real-World Implications.
Publisher: TAYLOR & FRANCIS LTDISSN: 0049-8254Frequency: 12 issues/year

XENOBIOTICA is a premier journal in the field of pharmacology and toxicology, published by Taylor & Francis Ltd. With an ISSN of 0049-8254 and E-ISSN 1366-5928, this journal has been at the forefront of research since 1971, providing critical insights and advancements up until 2024. It is recognized for its rigorous peer-reviewed content, occupying a third quartile ranking across various categories including Biochemistry, Health, Toxicology, and Pharmacology as of 2023. The journal serves as a pivotal platform for disseminating innovative findings that address the impact of xenobiotics on health and the environment, making it an essential resource for researchers, professionals, and students engaged in these multidisciplinary fields. While it does not currently offer open access, it is widely respected for its contribution to science, evidenced by its Scopus rankings across different areas of study. The journal encourages submissions that push the boundaries of knowledge and transform our understanding of the effects of chemical substances on living organisms.

THERAPEUTIC DRUG MONITORING

Elevating Standards in Drug Therapy Optimization
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0163-4356Frequency: 6 issues/year

THERAPEUTIC DRUG MONITORING, published by Lippincott Williams & Wilkins, is a prestigious journal that focuses on the critical area of pharmacology, with a specific emphasis on the therapeutic optimization of drug therapy. With an ISSN of 0163-4356 and an E-ISSN of 1536-3694, this peer-reviewed journal has been contributing valuable research and insights to the field since its inception in 1979. As of 2023, it holds a Q2 classification in the Pharmacology category, indicating its prominent role in advancing pharmaceutical sciences. The journal aims to enhance understanding of drug effectiveness and safety through rigorous studies on drug monitoring and individualized therapy, making it an essential resource for researchers, healthcare professionals, and students dedicated to improving patient care. With its solid standing reflected in Scopus rankings, including a rank of #103 in medical pharmacology and a 62nd percentile, THERAPEUTIC DRUG MONITORING continues to be a vital publication for those aiming to contribute to and stay informed about the latest developments in the field.

European Journal of Pharmacology

Fostering interdisciplinary collaboration in the realm of pharmacology.
Publisher: ELSEVIERISSN: 0014-2999Frequency: 24 issues/year

The European Journal of Pharmacology, a prestigious publication by Elsevier, serves as a vital resource in the field of pharmacology, offering rich insights into drug development and therapeutic applications. Since its inception in 1967, this journal has evolved to encompass groundbreaking research, including pharmacokinetics, toxicology, and innovative pharmacological methodologies, making it an essential platform for researchers and professionals alike. With an impressive impact factor that places it in the Q1 category of pharmacological journals and a Scopus ranking of #49 out of 313, the journal is recognized in the 84th percentile within its category, solidifying its significance in the academic community. Although the journal is not open access, it continues to attract contributions from leading scientists worldwide, ensuring that cutting-edge findings are disseminated effectively. The European Journal of Pharmacology not only highlights advancements in drug discovery and clinical applications but also promotes interdisciplinary collaboration, ultimately contributing to the progress of healthcare globally.

Current Drug Safety

Advancing the Frontiers of Drug Safety Research
Publisher: BENTHAM SCIENCE PUBLISSN: 1574-8863Frequency: 3 issues/year

Current Drug Safety is a distinguished peer-reviewed journal published by Bentham Science Publishers, focusing on the critical intersection of pharmacology and toxicology. With an ISSN of 1574-8863 and an E-ISSN of 2212-3911, this journal serves as a platform for the latest research and advances in drug safety, highlighting the importance of pharmacological assessments and toxicity evaluations in therapeutic development and public health. Reaching a broad international audience from its base in the United Arab Emirates, Current Drug Safety offers an invaluable resource for researchers, professionals, and students interested in the dynamic fields of drug research and safety management. Despite a current Q3 categorization in multiple pharmacology and toxicology quartiles for 2023, the journal continues to strive for excellence in the scholarly community, reflecting its commitment to disseminating high-quality research. While not operating under an open access model, articles can be accessed through institutional subscriptions and other platforms, ensuring valuable insights into drug safety are available to those who need it most.

Asian Journal of Pharmaceutics

Fostering global collaboration in pharmaceutical sciences.
Publisher: ASIAN JOURNAL PHARMACEUTICSISSN: 0973-8398Frequency: 4 issues/year

Asian Journal of Pharmaceutics, with ISSN 0973-8398 and E-ISSN 1998-409X, is a prominent publication in the field of pharmacology, toxicology, and pharmaceutics, published by the ASIAN JOURNAL PHARMACEUTICS. Since its inception in 2009, the journal has been committed to advancing the understanding of pharmaceutical sciences in Asia and beyond, encompassing innovative research, reviews, and perspectives from both established and emerging scholars. Despite its coverage discontinuation in Scopus, it continues to serve as a vital resource for researchers, professionals, and students aiming to explore the dynamic developments in drug formulation, delivery systems, and regulatory affairs. The journal's ranking in the 18th percentile within its category underscores its niche focus and relevance, making it an essential conduit for disseminating knowledge in the pharmaceutical domain. Open access options may enhance its reach and impact, allowing significant findings to be freely accessible to a global audience, thus fostering collaboration and knowledge exchange across borders.

Clinical Pharmacology in Drug Development

Elevating drug development through peer-reviewed excellence.
Publisher: WILEYISSN: 2160-7648Frequency: 6 issues/year

Clinical Pharmacology in Drug Development, published by WILEY, is a distinguished journal dedicated to advancing the field of pharmaceutical science and drug development. With a strong commitment to disseminating cutting-edge research, this journal serves as a crucial platform for professionals, researchers, and students aiming to enhance their understanding of pharmacological principles and innovations in medical therapeutics. Since its inception in 2012, the journal has consistently maintained a noteworthy presence in the academic community, currently achieving a Q2 ranking in both Pharmaceutical Science and Medical Pharmacology categories as of 2023. Although the journal operates under a subscription model, it is highly regarded for its rigorous peer-reviewed publications, offering insights into drug efficacy, safety, and regulatory challenges. Positioned at the intersection of clinical practices and pharmaceutical advancements, Clinical Pharmacology in Drug Development plays an essential role in bridging the gap between scientific research and real-world application, ensuring that the latest therapeutic strategies are optimized for patient care.

DRUG METABOLISM AND DISPOSITION

Your Gateway to Cutting-Edge Drug Research
Publisher: AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICSISSN: 0090-9556Frequency: 12 issues/year

Drug Metabolism and Disposition is a premier journal published by the American Society for Pharmacology and Experimental Therapeutics, focusing on crucial advancements in the fields of pharmaceutical sciences and pharmacology. Since its inception in 1973, this esteemed journal has established itself as a leading platform for innovative research, earning a prestigious Q1 rating in both Pharmaceutical Science and Pharmacology categories as of 2023. With an impressive Scopus ranking of #52 out of 183 in Pharmaceutical Science and #105 out of 313 in Pharmacology, it occupies a vital place in an increasingly competitive academic landscape. Researchers, professionals, and students alike benefit from its rigorous peer-reviewed articles that delve into drug metabolism processes and their physiological implications, making it an indispensable resource for anyone aiming to advance their understanding of drug disposition and efficacy. This crucial journal contributes significantly to the ongoing dialogue in pharmacology and toxicology, providing insights that help shape future therapeutic strategies and regulatory policies.